GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Home
/
insight
/
details

Revolutionizing Prostate Cancer Management: The Multifaceted Impact of Liquid Biopsy

NextEdge Admin

10 Feb 2024

3 min 0 sec

Liquid biopsy has emerged as a transformative tool in the management of advanced prostate cancer, offering multifaceted applications that significantly impact patient care. One key application lies in patient selection for targeted therapy, where liquid biopsy, exemplified by tests like FoundationOne® Liquid CDx, plays a pivotal role in identifying genetic alterations such as mutations in DNA damage repair genes (e.g., BRCA1/2). This molecular profiling guides clinicians in selecting patients who may benefit from precision therapies like PARP inhibitors, ushering in a personalized approach to treatment.

Real-time treatment monitoring represents another crucial dimension, facilitated by liquid biopsy’s ability to track treatment response dynamically. Analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) provides a more nuanced assessment compared to traditional markers like PSA, enabling clinicians to adapt treatment strategies promptly based on evolving genomic insights.

The utility of liquid biopsy extends to the early detection of disease progression, allowing for the identification of emerging clones and resistance mechanisms. Monitoring changes in ctDNA and CTCs offers valuable insights into the evolving genomic landscape of prostate cancer, supporting timely interventions and informed clinical decision-making.

Moreover, liquid biopsy contributes to predicting treatment responses through comprehensive analysis, including cfDNA assessment of genetic and epigenetic features. The identification of clonal hematopoiesis is a critical advancement, distinguishing true pathogenic alterations from CHIP variants, enhancing the accuracy of genomic interpretation.

In the realm of research and development, liquid biopsy has become a linchpin, contributing to a deeper understanding of prostate cancer evolution, heterogeneity, and resistance mechanisms. Its integral role in clinical trials facilitates the assessment of treatment responses and the identification of novel biomarkers, propelling advancements toward more effective and personalized therapeutic strategies. As ongoing research explores new dimensions of liquid biopsy, its influence in shaping the future of prostate cancer management is both profound and promising.